Mentioned:
AIAI +3.26% AIFF -8.77%
The future of clinical trials might be changing. And a publicly traded technology company in Canada is behind it.
What’s happening:
- NetraMark (CSE: AIAI) has entered into a new partnership with contract research organization Worldwide Clinical Trials to leverage their artificial intelligence platform for Phase II and Phase III clinical trials
Why it matters:
- Worldwide Clinical Trials is one of the largest contract research organizations globally, operating clinical trials and scientific research in more than 60 different countries
Going deeper:
- NetraMark’s proprietary artificial intelligence platform NetraAI is capable of sorting through complex datasets to uncover hidden patient subpopulations and identifying important factors that impact the effectiveness of drug targeting
- The new partnership between NetraMark and Worldwide Clinical Trials will initially be rolled out to clinical trials focused on neuroscience and oncology
The intrigue:
- Leveraging artificial intelligence for both drug discovery and clinical trials continues to be an emerging theme in Silicon Valley and Wall Street, with Google’s (NASDAQ: GOOG) spin out company Isomorphic Labs just recently raising more than half a billion dollars and Firefly Neuroscience (NASDAQ: AIFF) previously partnering with Hemostemix (TSXV: HEM) for a clinical trial focused on vascular dementia
